Abstract
The conserved cylindromatosis (CYLD) codes for a deubiquitinating enzyme and is a crucial regulator of diverse cellular processes such as immune responses, inflammation, death, and proliferation. It directly regulates multiple key signaling cascades, such as the Nuclear Factor kappa B [NFkB] and the Mitogen-Activated Protein Kinase (MAPK) pathways, by its catalytic activity on polyubiquitinated key intermediates. Several lines of emerging evidence have linked CYLD to the pathogenesis of various maladies, including cancer, poor infection control, lung fibrosis, neural development, and now cardiovascular dysfunction. While CYLD-mediated signaling is cell type and stimuli specific, the activity of CYLD is tightly controlled by phosphorylation and other regulators such as Snail. This review explores a broad selection of current and past literature regarding CYLD’s expression, function and regulation with emerging reports on its role in cardiovascular disease.
Keywords: Cardiovascular, CYLD, cylindromatosis, deubiquitination, K63, MAPK, NF-kB.
Current Drug Targets
Title:CYLD-Mediated Signaling and Diseases
Volume: 16 Issue: 4
Author(s): Bryan J. Mathis, Yimu Lai, Chen Qu, Joseph S. Janicki and Taixing Cui
Affiliation:
Keywords: Cardiovascular, CYLD, cylindromatosis, deubiquitination, K63, MAPK, NF-kB.
Abstract: The conserved cylindromatosis (CYLD) codes for a deubiquitinating enzyme and is a crucial regulator of diverse cellular processes such as immune responses, inflammation, death, and proliferation. It directly regulates multiple key signaling cascades, such as the Nuclear Factor kappa B [NFkB] and the Mitogen-Activated Protein Kinase (MAPK) pathways, by its catalytic activity on polyubiquitinated key intermediates. Several lines of emerging evidence have linked CYLD to the pathogenesis of various maladies, including cancer, poor infection control, lung fibrosis, neural development, and now cardiovascular dysfunction. While CYLD-mediated signaling is cell type and stimuli specific, the activity of CYLD is tightly controlled by phosphorylation and other regulators such as Snail. This review explores a broad selection of current and past literature regarding CYLD’s expression, function and regulation with emerging reports on its role in cardiovascular disease.
Export Options
About this article
Cite this article as:
Mathis J. Bryan, Lai Yimu, Qu Chen, Janicki S. Joseph and Cui Taixing, CYLD-Mediated Signaling and Diseases, Current Drug Targets 2015; 16 (4) . https://dx.doi.org/10.2174/1389450115666141024152421
DOI https://dx.doi.org/10.2174/1389450115666141024152421 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Single-cell RNA Sequencing: In-depth Decoding of Heart Biology and Cardiovascular Diseases
Current Genomics Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Recent Advances in Exercise Testing
Current Cardiology Reviews The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Targeting the Inflammatory Response in Healing Myocardial Infarcts
Current Medicinal Chemistry Is Nephrogenic Systemic Fibrosis a Disease of Fibrocytes?
Current Rheumatology Reviews Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Interest of Antioxidant Agents in Parasitic Diseases. The Case Study of Coumarins
Current Topics in Medicinal Chemistry Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Molecule of the Month
Current Topics in Medicinal Chemistry